Pharmacological methods of therapy in Parkinson’s disease

Código QR

Pharmacological methods of therapy in Parkinson’s disease

The review concerns modern pharmacological methods of Parkinson's disease treatment. The basic drugs used in practice are levodopa, dopamine receptor agonists, MAO-B inhibitors, anticholinergics, COMT inhibitors, and amantadine drugs. The article considers main features, assessment methods and...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Y. N. Bykov, T. B. Bender
Formato:	article
Lenguaje:	RU
Publicado:	Scientific Сentre for Family Health and Human Reproduction Problems 2016
Materias:	parkinson's disease pharmacological therapy dopamine Science Q
Acceso en línea:	https://doaj.org/article/d7637ef0dae24212bac37b15159635d2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Mobile computer technologies in personified therapy of Parkinson’s disease patients
por: Y. N. Bykov, et al.
Publicado: (2018)

Levodopa en la enfermedad de Parkinson: ¿Qué hemos aprendido?
por: Juri C,Carlos, et al.
Publicado: (2006)

Safinamide: an add-on treatment for managing Parkinson’s disease
por: Müller T
Publicado: (2018)

Using Graphene-Based Biosensors to Detect Dopamine for Efficient Parkinson’s Disease Diagnostics
por: Małgorzata Kujawska, et al.
Publicado: (2021)

Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson’s disease trial
por: R. Matthew Hutchison, et al.
Publicado: (2021)

Music Therapy and Parkinson’s Disease: A Systematic Review from 2015–2020
por: Manuel Joaquín Machado Sotomayor, et al.
Publicado: (2021)

The Retinal Posterior Pole in Early Parkinson’s Disease: A Fundus Perimetry and SD-OCT Study
por: Cesareo M, et al.
Publicado: (2021)

Diagnóstico precoz de enfermedad de Parkinson: neurospect del transportador de Dopamina
por: Díaz,Fernando, et al.
Publicado: (2002)

2D-DIGE as a strategy to identify serum protein biomarkers to monitor pharmacological efficacy in dopamine-dictated states of Parkinson’s disease and schizophrenia
por: Gupta AK, et al.
Publicado: (2019)

Severo edema inducido por la terapia dopaminérgica en la enfermedad de Parkinson. Caso clínico
por: Miranda C.,Marcelo, et al.
Publicado: (2017)

Parkinson's disease

A review of ropinirole prolonged release in Parkinson’s disease
por: Muhammad M Nashatizadeh, et al.
Publicado: (2009)

Pharmacological Modulation of Nrf2/HO-1 Signaling Pathway as a Therapeutic Target of Parkinson’s Disease
por: Yumin Wang, et al.
Publicado: (2021)

Journal of Parkinson's disease

Cerebrospinal Fluid Proteomics For Identification Of α2-Macroglobulin As A Potential Biomarker To Monitor Pharmacological Therapeutic Efficacy In Dopamine Dictated Disease States Of Parkinson’s Disease And Schizophrenia
por: Gupta AK, et al.
Publicado: (2019)

Bright Light Therapy for Parkinson Disease: A Literature Review and Meta-Analysis of Randomized Controlled Trials
por: Hsu-Tung Huang, et al.
Publicado: (2021)

Gene Therapeutic Approaches for the Treatment of Mitochondrial Dysfunction in Parkinson’s Disease
por: Jannik Prasuhn, et al.
Publicado: (2021)

Therapeutic strategies in the early stages of Parkinson’s disease: a cross-sectional evaluation of 15 years’ experience with a large cohort of Romanian patients
por: Szász JA, et al.
Publicado: (2019)

Examining the Toxicity of α-Synuclein in Neurodegenerative Disorders
por: Frank Y. Shan, et al.
Publicado: (2021)

Neurophysiological Predictors of Response to Medication in Parkinson's Disease
por: Saša R. Filipović, et al.
Publicado: (2021)

Comparison of strength training, aerobic training, and additional physical therapy as supplementary treatments for Parkinson’s disease: pilot study
por: Carvalho A, et al.
Publicado: (2015)

SARS-COV-2 induced Parkinsonism: The first case from the sub-Saharan Africa
por: Biniyam A. Ayele, et al.
Publicado: (2021)

RISK FACTORS OF COGNITIVE IMPAIRMENT IN PARKINSON’S DISEASE AND DISCIRCULATORY ENCEPHALOPATHY
por: S. B. Sayutina, et al.
Publicado: (2017)

Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease
por: Daniel D Truong
Publicado: (2009)

Bupropion interferes with the image diagnosis of Parkinson's disease
por: Lin CH, et al.
Publicado: (2017)

Cognitive behavioral therapy for depression in Japanese Parkinson's disease patients: a pilot study
por: Shinmei I, et al.
Publicado: (2016)

Adverse drug reaction suggests by a clinical vignette
por: Finestone AJ
Publicado: (2011)

Composition of intestinal flora affects the risk relationship between Alzheimer's disease/Parkinson's disease and cancer
por: Zhongci Hang, et al.
Publicado: (2022)

Electroconvulsive Therapy as a Corrector for Certain Side Effects of Antipsychotic Therapy
por: Yu. V. Bykov, et al.
Publicado: (2020)

Anti-Inflammatory Effects of the Novel Barbiturate Derivative MHY2699 in an MPTP-Induced Mouse Model of Parkinson’s Disease
por: Seulah Lee, et al.
Publicado: (2021)

Cognitive behavioral group therapy versus psychoeducational intervention in Parkinson’s disease
por: Berardelli I, et al.
Publicado: (2018)

NRF2 Activation and Downstream Effects: Focus on Parkinson’s Disease and Brain Angiotensin
por: Juan A. Parga, et al.
Publicado: (2021)

Evaluation of α-synuclein and apolipoprotein E as potential biomarkers in cerebrospinal fluid to monitor pharmacotherapeutic efficacy in dopamine dictated disease states of Parkinson’s disease and schizophrenia
por: Gupta AK, et al.
Publicado: (2019)

Synaptic Density and Neuronal Metabolic Function Measured by Positron Emission Tomography in the Unilateral 6-OHDA Rat Model of Parkinson’s Disease
por: Nakul Ravi Raval, et al.
Publicado: (2021)

The efficacy of a “cocktail therapy” on Parkinson’s disease with dementia
por: Zhang C, et al.
Publicado: (2019)

Terapia neuroprotectora de la Enfermedad de Parkinson
por: Miranda,Marcelo, et al.
Publicado: (2004)

A practical method for the detection of freezing of gait in patients with Parkinson’s disease
por: Kwon Y, et al.
Publicado: (2014)

INCREASED SPONTANEOUS APOPTOSIS OF PERIPHERAL BLOOD LYMPHOCYTES FROM PATIENTS WITH PARKINSON’S DISEASE
por: S. N. Pchelina, et al.
Publicado: (2014)

Melatonin Attenuates Neuroinflammation by Down-Regulating NLRP3 Inflammasome via a SIRT1-Dependent Pathway in MPTP-Induced Models of Parkinson’s Disease
por: Zheng R, et al.
Publicado: (2021)

Aplicaciones de la musicoterapia en la medicina
por: Zárate D,Patricia, et al.
Publicado: (2001)